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Glucocorticoid Receptor-mediated 
transactivation is hampered by 
Striatin-3, a novel interaction 
partner of the receptor
Ioanna Petta1,2,3,4, Nadia Bougarne1,2,5, Jolien Vandewalle3,4, Lien Dejager3,4, Sofie 
Vandevyver3,4, Marlies Ballegeer3,4, Sofie Desmet1,2,5, Jonathan Thommis1,2,5, Lode De 
Cauwer1,2,5, Sam Lievens1,2, Claude Libert3,4, Jan Tavernier1,2,6 & Karolien De Bosscher1,2,5,6
The transcriptional activity of the glucocorticoid receptor (GR) is co-determined by its ability to recruit 
a vast and varying number of cofactors. We here identify Striatin-3 (STRN3) as a novel interaction 
partner of GR that interferes with GR’s ligand-dependent transactivation capacity. Remarkably, STRN3 
selectively affects only GR-dependent transactivation and leaves GR-dependent transrepression 
mechanisms unhampered. We found that STRN3 down-regulates GR transactivation by an additional 
recruitment of the catalytic subunit of protein phosphatase 2A (PPP2CA) to GR. We hypothesize the 
existence of a functional trimeric complex in the nucleus, able to dephosphorylate GR at serine 211, 
a known marker for GR transactivation in a target gene-dependent manner. The presence of STRN3 
appears an absolute prerequisite for PPP2CA to engage in a complex with GR. Herein, the C-terminal 
domain of GR is essential, reflecting ligand-dependency, yet other receptor parts are also needed to 
create additional contacts with STRN3.
Glucocorticoids (GC) exert effects at multiple levels of cellular functionality, including energy metabolism, cell 
fate and immune response. The majority of actions by hormonal GC ligands are mediated by the glucocorticoid 
receptor (GR), a transcription factor that can regulate gene expression in a positive or negative manner1, 2. To 
exert its gene regulatory effects, GR interacts, mainly via its ligand binding domain (LBD)3 with different proteins 
including other transcription factors, modifying enzymes, chromatin modulators, scaffold proteins, co-activators, 
co-repressors and co-chaperone proteins4.
GR-mediated gene promoter activation involves DNA binding of a homodimeric GR on a palindromic GC 
response element (GRE) in the promoter (simple GRE), from a coordinated DNA binding of a GR/transcrip-
tion factor complex onto a so-called composite GRE or from a GR/transcription factor tethering mechanism. 
The latter two mechanisms can also form the basis for GR-mediated promoter repression5, 6. Recently, also a 
role for monomeric GR in direct target gene activation was discovered. More specifically, monomeric GR can 
bind to half sites and promote gene activation7. In an independent study using endogenous GCs, monomeric 
GR-binding to half-sites was found to be even more prevalent than homodimer binding, mediating transcription 
of tissue-specific target genes. In contrast, exogenous GC treatment induces GR dimer assembly to classic pal-
indromic site-containing promoters of ligand-dependent genes. This event is at the expense of monomeric GR 
binding which vanishes from promoters of repressed genes8. These finding are important for the improvement of 
GR-based treatments. Among the widely studied anti-inflammatory actions of GCs is the GR-mediated repres-
sion of the activity of pro-inflammatory transcription factors such as NF-κB and AP1 via protein-protein inter-
actions6. Although GCs are commonly used in the clinic for their potent anti-inflammatory properties, GCs are 
1Receptor Research Laboratories, Cytokine Receptor Lab, VIB, Center for Medical Biotechnology, Ghent, Belgium. 
2Department of Biochemistry, Ghent University, Ghent, Belgium. 3Center for Inflammation Research, VIB, Ghent, 
Belgium. 4Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. 5Receptor Research 
Laboratories, Nuclear Receptor Lab, VIB, Medical Biotechnology Center, Ghent, Belgium. 6Cancer Research Institute 
Ghent (CRIG), Ghent, Belgium. Nadia Bougarne and Jolien Vandewalle contributed equally to this work. Claude 
Libert, Jan Tavernier and Karolien De Bosscher jointly supervised this work. Correspondence and requests for 
materials should be addressed to K.D.B. (email: karolien.debosscher@vib-ugent.be)
Received: 3 January 2017
Accepted: 19 July 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNTIfIC RePoRTS | 7: 8941  | DOI:10.1038/s41598-017-09246-6
not always effective as a treatment due to the onset of glucocorticoid resistance (GCR); a phenomenon observed 
in many inflammatory conditions9.
GR’s post-translational modifications, such as phosphorylation, play a predominant role in determining and 
fine-tuning the receptor’s function10, 11. Accordingly, phosphorylated residues already described to influence the 
transcriptional activity of human GR are serine 203 (S203) and serine 211 (S211). Phosphorylated GR at S203 
(pS203) is cytoplasmically contained and fails to bind GRE-dependent promoters, suggesting that GR pS203 is 
a transcriptionally inactive form of the GR. However, GR is transcriptionally more active when phosphorylated 
at S211, due to a conformational change, and an increased recruitment at GRE-containing promoters has been 
observed12.
By using the high-throughput mammalian protein-protein interaction trap (MAPPIT), we identified human 
Striatin-3 or alternatively S/G2 nuclear autoantigen (SG2NA) isoform alpha, STRN3α (hereafter referred to as 
STRN3) as a novel interaction partner of GR that negatively affects the GR-dependent transactivation pathway. 
STRN3 belongs to the striatin family of proteins, which consists of three members, namely Striatin, Striatin-3 
and Zinedin, acting mainly as scaffold proteins13. The striatin family of proteins associates with kinases as well 
as phosphatases, including the major eukaryotic serine/threonine protein phosphatase 2 A (PP2A), forming 
the striatin-interacting phosphatase and kinase (STRIPAK) complex14, 15. STRN3 family members share a com-
mon protein structure consisting of four well-defined domains i.e. the caveolin-binding domain, the coiled-coil 
domain, the Ca2+-calmodulin-binding domain and the tryptophan-aspartate (WD)-repeat domain16 (Fig. 1A). 
Here, we found that the recruitment of STRN3 to GR indirectly suppresses GR transactivation, by allowing 
PPP2CA to be additionally recruited to facilitate GR dephosphorylation at S211. Our data thus support a role for 
STRN3 as an important check-point for GR functionality.
Results
STRN3 is a novel interaction partner of GR. Array MAPPIT17, a two-hybrid technology for the identi-
fication and analysis of protein-protein interactions in mammalian cells18–20 (Fig. 1B and C), was used to screen 
for interaction partners of GRα21 (hereafter referred to as GR). We identified Striatin-3 (STRN3) (Fig. 1A) as a 
novel specific interaction partner of GR (Fig. 1C). The interaction between STRN3 and GR was further enhanced 
upon activating the receptor with the synthetic GR agonist Dexamethasone (Dex) (Fig. 1C). Although the inter-
action was independently confirmed using co-immunoprecipitation analysis (Fig. 1D), the MAPPIT assay proved 
more sensitive in detecting a Dex ligand-enhanced interaction. To find out in which subcellular compartment 
endogenous GR and STRN3 reside, A549 cells were treated with solvent or DEX and subject to indirect immu-
nofluorescence analysis (Fig. 2). In solvent-treated cells, GR was predominantly cytoplasmic, while STRN3 signal 
was present both in cytoplasm and nucleus. The subcellular distribution changed dramatically upon adding DEX 
for 2 h. Both GR and STRN3 displayed a predominantly nuclear phenotype, in support of a co-localization. To 
strengthen the hypothesis, the average Pearson correlation coefficients (PCC), indicative of a co-localization, of 
whole fields of 5 recorded images of at least 10 cells/field were determined as described by Dunn et al.22. PCC 
values range from 1 for two images of which fluorescence intensities are perfectly, linearly related, to −1 for two 
images of which fluorescence intensities are perfectly, but inversely, related to one another. The average Pearson 
correlation coefficient of the solvent control set-up for GR and STRN3 was 0.63 while the Pearson correlation 
coefficient of the DEX set-up for GR and STRN3 increased to a value of 0.90, indicating a linear relation between 
the signals for GR and STRN3. In conclusion, following DEX activation both proteins are most likely able to inter-
act in the nucleus. In support of a cell type independent effect, similar data were obtained in HeLa cells, which 
have been reported to contain substantial amounts of endogenous STRN3 (Supplementary S1).
STRN3 is an inhibitor of the transactivation function of GR. To test the effect of STRN3 on 
GR-mediated transcription in mammalian cells, we used both over-expression and silencing approaches. First, 
a glucocorticoid response element (GRE)-dependent reporter gene construct was transfected in HEK293T cells, 
with an expression plasmid for GR since these cells endogenously do not contain functional GR23. Figure 3A 
demonstrates that STRN3 can inhibit the Dex-mediated transactivation capacity of GR. The last two control 
lanes show that STRN3 specifically affects GR-mediated gene expression and does not influence the activity of the 
reporter in the absence of over-expressed GR. Similar results were observed using HeLa cells, confirming that the 
effect of STRN3 is cell-type independent (Supplementary S2). To find out whether endogenous STRN3 modulates 
GR-mediated gene activation, we silenced endogenous STRN3 and monitored both GRE-dependent reporter 
gene activity (Fig. 3B and C) and endogenous GRE-dependent target genes (Fig. 3E). A549 cells were used, in 
which we previously optimized the silencing technology24 and which advantageously contain endogenous GR. 
STRN3 knockdown increased the Dex-mediated GRE-dependent reporter gene activity (Fig. 3B). Figure 3C 
represents the absolute counts of the luciferase activity of Figure 3B. Both Figure 3B and C show that STRN3 
silencing does not cause a significant effect on GR basal activity in the absence of Dex. Figure 3D demonstrates an 
efficient knockdown of STRN3 of over 80%. In line herewith, the Dex-induced GRE-dependent mRNA expres-
sion of DUSP1, encoding MKP-1, PER1, ZFP and ECI2 (Fig. 3E), are also enhanced upon silencing of STRN3. 
Interestingly, the levels of ECI2 are enhanced in a statistical significant manner in the absence of Dex. We believe 
this result may reflect a promoter specific effect. Moreover, we could confirm the effect of STRN3 silencing on GR 
transactivation capacity by using a different STRN3 specific siRNA (Supplementary 3).
Activated GR also inhibits gene expression in a DNA-independent manner, via protein-protein interactions; 
a mechanism referred to as transrepression. To investigate whether endogenous STRN3 may influence transre-
pression, we studied the impact of STRN3 silencing on the ability of GR to block the activity of NF-κB, using a 
TNF-induced NF-κB-dependent reporter gene as read-out. Figure 3F demonstrates that STRN3 does not affect 
the NF-κB-targeting transrepression function of GR. Together; our results indicate that STRN3 may be a specific 
inhibitor of GR-mediated transactivation, but not transrepression.
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STRN3 inhibits the transactivation function of other nuclear receptors. As STRN3 was previously 
described to reduce the activity of ERα25, we asked whether the observed effect of STRN3 was specific for the 
steroid receptor class of nuclear receptors, or else could be expanded to other nuclear receptor family members. 
Hereto, we compared the effect of STRN3 over-expression on progesterone-driven PR activity (Fig. 4A) and on 
GW647-driven PPARα activity (Fig. 4B), using their respective promoter elements coupled to luciferase report-
ers. In analogy with the results using GR, upon over-expression of STRN3 the ligand-mediated transactivation 
ability of both receptors is decreased. For PR, a decrease of 24% was observed and an even more prominent effect, 
almost 50%, is obtained for activated PPARα-driven PPRE-Luc activity (Fig. 4B). Already at the lowest concen-
tration of transfected plasmid DNA, STRN3 was able to significantly inhibit PPARα transactivation.
STRN3 decreases GR transactivation via the dephosphorylation of serine S211. In human GR, 
phosphorylation of serine 211 (S211, mouse S220, rat S232) in its N-terminal domain is linked to receptor trans-
activation26 (Fig. 5A). Since we identified a STRN3-mediated decrease of GR transactivation, it was tempting to 
speculate that STRN3 may alter the phosphorylation status of S211 of human GR. Over-expressing increasing 
amounts of STRN3 in A549, as indicated, resulted in a gradual decrease in the cellular pool of GR, specifically 
Figure 1. STRN3 is a novel interaction partner of the Glucocorticoid receptor. (A) Protein structure of STRN3. 
Depicted are its representative domains i.e. the Caveolin-binding domain (CaV), the coiled-coil domain (C-C),  
the Calmodulin-binding domain (CaM) and the tryptophan-aspartate (WD)-repeats at its C-terminal domain. 
(B) Schematic representation of MAPPIT technology. GR is fused to a mutated Leptin receptor, unable to 
recruit STAT3. The STRN3 pray is bound to a gp130 fragment with functional STAT3 recruitment sites. Only 
upon interaction of GR with STRN3 and stimulation with Leptin or Leptin + Dex, the Leptin receptor signaling 
cascade is reconstituted, leading to STAT3 activation, translocation to the nucleus and activation of the reporter 
gene (luciferase). (C) For the MAPPIT experiments, HEK293T cells were transfected with GR bait, rPAP1-Luc 
reporter and STRN3 prey or empty vector and stimulated with vehicle (medium, not shown in the graph) or 
leptin plus medium (−) or with leptin plus Dex (+) for 24 h (more details in Methods). The graphs represent 
the fold change induction to the vehicle-treated condition. Empty vector was used as negative control. The 
graph represents pool data from three independent experiments. (D) The interaction of GR with STRN3 was 
confirmed with co-immunoprecipitation (Co-IP). HEK293T cells were transfected with 3 μg Flag-STRN3 
(96 kDa) and 4 μg of CFP-GR (117 kDa) (or empty vector so that total transfected DNA is 7 μg) and stimulated 
either with vehicle (media) or with 1 μM Dex for 2 h. Cells were lysed and immunoprecipitated with M2-Flag 
beads. Over-expression of CFP-GR with M2-Flag beads incubation was used as negative control for the IP 
assay. Precipitates and input lysates were immunoblotted for GR and Flag. The blots show one representative 
experiment out of three performed (full-length blots are provided in Supplementary S11).
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phosphorylated at S211 upon Dex treatment (Fig. 5B). Of note, the highest transfected STRN3 concentration 
leads to an 80% repression of S211 phosphorylation (Supplementary S4A).
Complementary herewith, the opposite approach, i.e. silencing of STRN3, demonstrated an increment in the 
level of GR specifically phosphorylated at S211 upon Dex, of almost 40% (Fig. 5C, Supplementary S4B). Figure 5D 
demonstrates an efficient knockdown of STRN3. Taken together, these results support that the mechanism by 
which STRN3 inhibits the transactivation function of GR may be directly linked to receptor dephosphorylation 
(quantification of the bands is provided in Supplementary S4A and B). A kinetics experiment further showed that 
the effect of STRN3 on GR phosphorylation is most clear after 90 min Dex (Supplementary S5A and B).
Next, we wanted to test how STRN3 impacts on the nuclear pool of phosphorylated GR, which is able to 
directly mediate transactivation. Hereto, YFP-STRN3 was over-expressed in A549 cells, and lysates were sub-
jected to a cytoplasmic and nuclear fractionation analysis. In presence of excess STRN3, a decrease in the 
Dex-mediated GR phosphorylation at S211 is prominent in the nuclear fraction, while no differences on GR dis-
tribution between cytoplasmic and nuclear compartments were apparent when comparing the same treatments 
(Fig. 5E). Hence, the effect of STRN3 on GR phosphorylation does not affect the ability of GR to accumulate in 
the nucleus, but targets the transactivation function of GR when still present within the nuclear compartment. 
Because the pS211 GR signal specifically decreases in the nucleus in presence of over-expressed STRN3 (Fig. 5E), 
we postulate that the interaction in the nucleus is most probably the functionally relevant interaction.
To strengthen our hypothesis that STRN3 hampers the activity of GR in a phosphorylation-dependent man-
ner, we monitored GR transactivation upon replacing wild-type (WT) GR with a GR variant in which S211 is 
mutated to Alanine (A), and which is expected to have a lower, yet residual, activity compared to the WT GR27. 
STRN3 has now lost the ability to inhibit GR transactivation (Fig. 6A), confirming our earlier data that STRN3 
mediates its effect by targeting phosphorylated GR at S211. To confirm that this mutation does not affect the 
interaction, which may in essence lead to the same conclusion, again a co-immunoprecipitation was performed. 
The result demonstrates that Flag-GR S211A is still able to physically interact with YFP-STRN3 (Fig. 6B).
PPP2CA mediates the effects of STRN3 on GR phosphorylation. STRN3 is a scaffold protein 
without enzymatic activity yet interacts with phosphatases and kinases. More specifically, STRN3 can bind to 
different subunits of protein phosphatase 2 A (PP2A) such as PPP2R1B, PPP2R1A, PPP2CB and PPP2CA16, 28. 
Ingenuity pathway analysis (IPA) was used to identify common phosphatases shown to bind both STRN3 and 
GR. This yielded two common phosphatases, namely, PPP2R1A and PPP2CA (Fig. 7A). Should one of these 
phosphatases be directly involved, specific silencing would maintain levels of phosphorylated S211 upon Dex 
despite the presence of STRN3. Following an efficient knockdown of PPP2CA protein of over 60% (Fig. 7B lanes 
5–8, Supplementary S6), this prediction is exactly the result as observed in Fig. 6B. Upon siRNA targeting of 
PPP2R1A, S211 phosphorylation levels of GR were not affected (data not shown).
Having found that PPP2CA mediates the effects of STRN3, we next reasoned that the three proteins might 
co-exist in the same protein complex. Co-immunoprecipitation analysis following over-expression of all three 
Figure 2. DEX treatment of A549 cells supports co-detection of endogenous GR and STRN3 in the nucleus. 
A549 cells were seeded on coverslips and incubated in phenol-red free and serum-free medium for 4 h. Cells 
were treated with either solvent or 1 µM of DEX, for 2 h following by indirect immunofluorescence analysis 
to detect GR (green signal) and/or STRN3 (red signal). Cell nuclei are visualized using DAPI (blue signal). 
Assessment of co-localization of the protein signal for GR and STRN3 (middle frame) was performed by 
correlation statistics using the Olympus Fluoview version 4.2 software. The image is a representative result of 5 
recorded images, with each field containing minimally 10 cells.
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Figure 3. STRN3 is an inhibitor of GR trans-activation. (A) HEKT293T cells were transfected in 96-well plate 
with 30 ng of Flag-GR, 15 ng of GRE-luc and over-expression of STRN3, 30 ng and 60 ng, as indicated (or empty 
vector so that total transfected DNA is 110 ng). Cells were treated with 1 μM Dex or vehicle, for 6 h. In the last 
two lanes, Flag-GR was not over-expressed. (B) A549 cells stably transfected with GRE-Luc reporter were 
transfected with 50 nM siRNA On Target plus (Dharmacon) for human STRN3. Cells were treated with 1 μM 
Dex or vehicle for 24 h and processed for luciferase measurement. (C) Representation of the absolute luciferase 
values of graph in (B). (D) WT A549 cells were transfected with STRN3-specific siRNA or control siRNA (as 
in B and C) and stimulated with 1 μM Dex or vehicle for 6 h before lysis and RNA extraction. A549 cells treated 
as in (B,C) were processed for qPCR to determine the endogenous STRN3 levels and (E) the levels of the GR-
dependent genes DUSP1, PER1, ZFP and ECI2. (F) A549 cells stably transfected with NF-κB-Luc reporter are 
transfected with human STRN3-specific siRNA or control siRNA (as in B,C,E). Cells are subsequently treated 
with vehicle or with 1000 U/ml of human TNF or pre-treated with 1000 U/ml of human TNF for 1 h followed by 
1 μM Dex for 6 h or with 1 μM Dex alone for 6 h. All data are represented as fold change to the vehicle-treated 
condition. The graphs represent pooled data from three independent experiments.
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components in HEK293T (Fig. 7C) demonstrates that GR, PPP2CA and STRN3 may be part of one complex, 
potentially explaining effects on GR phosphorylation and subsequently on transactivation. In line with our previ-
ous results, using co-immunoprecipitation to study the interaction between GR and STRN3 (Figs 1D and 6B), no 
ligand effect of Dex on the formation of the trimeric complex is observed. As expected, we observe a strong inter-
action between PPP2CA and STRN3 conform literature29. Surprisingly, we do not detect a previously described 
interaction between over-expressed GR and PPP2CA30. Our results indicate STRN3 as a crucial scaffold protein 
facilitating the interaction between GR and PPP2CA, which serves to modulate the function of GR. Since endog-
enous STRN3 could not be detected due to poor antibody quality specifically for IP and Western analysis, we 
checked in A549 cell lysate whether over-expressed and detectable Flag-STRN3 could pull down endogenous 
phosphorylated GR and/or endogenous PPP2CA. The result in Supplementary S7 demonstrates that upon immu-
noprecipitation of Flag-STRN3 endogenous GR phosphorylated at S211 was enriched already in absence of Dex. 
Although in presence of Dex, the co-immunoprecipitated pS211GR signal is similar, we speculate that this result 
nevertheless reflects an ongoing dephosphorylation, since in the input the ratio of pS211 GR for Dex-treated 
cells compared to solvent-treated cells is much higher. Co-immunoprecipitation analysis also demonstrated an 
additional interaction with endogenous PPP2CA, which again points to the presence of all three proteins in one 
complex.
To validate the importance of STRN3 for the recruitment of PPP2CA in the same complex with GR, we 
applied a phosphatase activity assay to compare the levels of phosphatase activity in the complexes in absence and 
presence of STRN3. Figure 7D shows that a GR-associated phosphatase activity is only detectable when Flag-GR, 
YFP-STRN3 and PPP2CA are over-expressed, confirming that STRN3 may be prerequisite for the recruitment of 
PPP2CA in the proximity of GR, whilst in the absence of STRN3, PPP2CA is not able to bind to GR.
The C-terminal domain of GR is important for a proper formation of the trimeric complex. We 
used various Flag-tagged GR deletion mutants encompassing different functional domains (Fig. 8A) of human 
GR to identify which region(s) is/are important for the interaction with STRN3 and PPP2CA (Fig. 8B). GR 
mutants carrying a deletion in the NTD or DBD, were all found to strongly interact with YFP-STRN3 (Del1-401, 
Del1-416, Del417-486). Actually, in all deletion variants of GR in which LBD is still present, a strong interaction 
with STRN3 is observed, suggesting an important role for this domain of GR. However, the interaction of GR 
with STRN3 is not lost, only weaker, when the GR-LBD is deleted (Del487-777). This result points to a role for 
(an)other domain(s) besides the LBD. Yet, if only the N-terminal of the GR is withheld, then the interaction is 
lost (Del417-777), dismissing this domain as an important contact point. Since a weak interaction is restored 
using GR Del487-777, in which both NTD and DBD are present, we could envisage a weak contact point involv-
ing the DBD. Contrary to this assumption, the deletion mutant Del417-486, which keeps only NTD and LBD 
intact, exhibits a strong interaction. However, bearing in mind LBD is still present in this mutant, it may be that 
interaction surfaces are more favorable between GR LBD and STRN3 for this particular GR mutant lacking only 
DBD. At any rate, domain analysis might not reflect proper folding and so misleading conclusions could be made. 
Nevertheless, our observations consistently support that the LBD of GR is important for this interaction, even 
though the LBD alone may not be sufficient for an optimal interaction.
We next studied which GR mutants allow for an additional association of PPP2CA and, hence, trimeric com-
plex formation. As HEK293T cells express high levels of endogenous PPP2CA, no over-expression was needed 
to detect the binding of endogenous PPP2CA to YFP-STRN3 and Flag-GR deletion mutants. GR LBD is a pre-
requisite for the binding of PPP2CA to the trimeric complex since in both experimental set-ups using GR minus 
its LBD (Del487-777 and Del417-777), PPP2CA binding is completely absent (Fig. 8B). Even in the set-up using 
GR Del487-777, which still allows for a weak interaction with STRN3, the absence of GR LBD prevents a physical 
recruitment of PPP2CA to the complex, emphasizing again the importance of GR LBD. PPP2CA binds to the 
Figure 4. STRN3 inhibits PR and PPARα trans-activation. (A) HEK293T cells were transfected with Flag-PR 
(30 ng) along with its respective PRE-Luc reporter (15 ng) and with 30 ng or 60 ng of Flag-STRN3. The cells were 
stimulated with 1 μM progesterone (or vehicle) for 24 h as indicated. (B) HEK293T cells were transfected with 
Flag-PPARα (30 ng) along with its respective PPRE-Luc reporter (15 ng) and with 30 ng or 60 ng of Flag-STRN3 
(or empty vector so that total transfected DNA is 110 ng). The cells were stimulated with 1 μM GW647 (or 
vehicle) for 24 h as indicated. The graphs represent pool data from three independent experiments.
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coiled-coil domain of STRN3, located close to the N-terminal domain of the STRN3 protein31. Consequently, 
we hypothesize that the LBD of GR interacts with STRN3 so that the coiled-coil domain of STRN3 can bring 
PPP2CA physically to GR LBD, from where it can reach its target, i.e. the N-terminally localized phosphorylated 
S211. In conclusion, our results suggest multiple contact points between GR and STRN3 and a prerequisite for GR 
LBD to enable a functional trimeric complex with PPP2CA, leading to a model as depicted in Fig. 8C.
Discussion
Because of the role of GR in different biological pathways and its use as a drug target32, analysis of its interactome 
contributes to comprehend its regulatory pathways. Here, STRN3 was identified as a novel interaction partner of 
liganded GR. Immunofluorescence analysis demonstrated that these two endogenous proteins co-localize in the 
nucleus, indicating the involvement of STRN3 in GR’s nuclear actions.
Figure 5. STRN3 mediates the dephosphorylation of GR at serine 211. (A) Protein structure of human GR with 
its respective domains (NTD, DBD, HR, LBD) and the phosphorylation sites indicated (S, serine, T, threonine). 
(B) A549 cells were transfected in 6-wellplate with gradient amounts of YFP-STRN3 plasmid, 400 ng, 800 ng, 
1600 ng or mock DNA (empty vector was used so that total transfected DNA is 2 μg/well) and stimulated 
with vehicle (−) or 1 μM Dex (+) for 2 h. The cells were lysed and processed for immunoblotting against GR 
phosphorylated at S211 (GR S211), total GR (86 kDa) and GAPDH (36 kDa). (C) A549 cells were transfected 
with 50 nM of STRN3-specific siRNA in 6-wellplate and stimulated with vehicle (−) or with 1 μM Dex (+) 
for 2 h. Samples were processed either for immunoblotting against GR phosphorylated at S211, total GR and 
GAPDH (The blots show one representative experiment out of three performed) or for (D) RNA isolation 
and qPCR to determine the endogenous levels of STRN3 and the efficiency of STRN3 silencing (statistics are 
not performed as data represent a technical triplicate). (E) YFP-STRN3 (or mock plasmid, empty vector) was 
over-expressed in A549 cells at a concentration of 6 μg in 10 cm plates and stimulated with vehicle (−) or with 
1 μM Dex (+) for 2 h. Cells were lysed and separated into cytoplasmic and nuclear fractions. Cellular fractions 
were analyzed by gel electrophoresis and immnunoblotted using antibodies against GR phosphorylated at 
S211, total GR (86 kDa), (YFP-) STRN3 (122 kDa), Lamin A/C (70 kDa, nuclear marker) and GAPDH (36 kDa, 
cytoplasmic marker). The blots show one representative experiment out of three performed (full-length blots of 
5B, 5C and 5E are provided in Supplementary S12, S13 and S14, respectively).
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Over-expression of STRN3 decreased GR transactivation while silencing enhanced GR transactivation. In 
line herewith, STRN3 silencing also augmented endogenous mRNA levels of the GR-inducible target genes 
DUSP1, encoding MKP1, a potent anti-inflammatory mediator33, PER1, ZFP and ECI2. Of note, the levels of 
ECI2 were enhanced upon silencing of STRN3 even in the absence of Dex treatment. Since ECI2 is a PPARα/
GRα co-controlled gene34 and PPARα may be also a target of STRN3 (Fig. 4B) it is tempting to speculate that 
the different regulation of ECI2 might be ascribed to an increased level control of this particular gene promoter. 
Interestingly, silencing of STRN3 did not interfere with the trans-repression pathway of GR (Fig. 3E) indicating 
that STRN3 may influence only the dimerization-dependent actions of GR. Phosphorylation of GR at S211 is 
a known prerequisite for the transcriptional activity of the receptor10, 27, 35. Over-expression of STRN3 causes 
decreased phosphorylation of GR at S211, whilst silencing of STRN3 leads to the enhancement of GR phos-
phorylation at the same residue. By using a GR mutant of S211 (S211A) we showed that the negative impact of 
STRN3 on GR transactivation is phosphorylation-dependent. Since the striatin family of proteins lacks enzymatic 
activity, a phosphatase may be recruited within the same complex that can alter the phosphorylation status of 
GR in the presence of STRN3. Tan and colleagues described a negative effect of rat STRN3γ on the actions of 
human Estrogen receptor α through dephosphorylation of the receptor at S118 by the catalytic subunit of PP2A, 
PPP2CA25. Although according to IPA, PPP2R1A could also be a candidate, in accord with the study of Tan et 
al. on ERα, only PPP2CA could be identified as the responsible enzyme dephosphorylating GR upon STRN3 
over-expression. Its silencing lifts the negative effect of STRN3 on GR’s phosphorylation status, which further 
strengthens the hypothesis of a trimeric complex. Following amino acid sequence alignment analysis of human 
ERα with human GR, we observe that S118 of ERα does not correspond to S211 of GR (Supplementary S8), 
indicating a different mechanism of action by which STRN3 and PPP2CA control the activity of these two dif-
ferent, yet related, receptors. Our results indicate that STRN3 may act as an inhibitor not only of steroid but also 
of peroxisome proliferator-activated nuclear receptors. Of note, STRN3 has been described in the literature to 
modulate the actions of ER, as mentioned above, but also of the Mineralocorticoid receptor (MR)36. Apart from 
the nuclear effect of STRN3 on ER, it is also involved in the receptor’s membrane associated actions. More spe-
cifically, over-expression of striatin in endothelial cells resulted in an increase in ERα in the membrane-enriched 
fraction, containing EGFR and IGF-1 receptor (IGF-1R), and a slight decrease in nuclear ERα. Striatin serves as 
a scaffold directing ERα to the plasma membrane and bridges ERα with the GPCR (Gαi) complex to facilitate 
assembly of a membrane signaling complex required for rapid estrogen extra-nuclear activation of MAPK, Akt, 
and eNOS in endothelial cells37–39. A similar mechanism has been proposed for Striatin and MR. Accordingly, 
in endothelial cells and murine heart tissue, complexes between striatin and MR have been described that can 
be disrupted by aldosterone but cannot be restored by spironolactone40, 41. Activation of MR by high levels of 
aldosterone increases striatin levels in vascular cells and in tissues of mouse models with elevated aldosterone 
concentrations40, 42. Lowering striatin levels in endothelial cells reduces the aldosterone-mediated non-genomic 
Figure 6. The effect of STRN3 on GR activity is phosphorylation-dependent but not its interaction with 
GR. (A) HEK293T cells were transfected (in 96-wellplate) with 30 ng of WT Flag-GR or with the GR mutant 
Flag-GR S211A along with 15 ng of the respective GRE-Luc reporter and 60 ng of Flag-STRN3 plasmid where 
indicated (empty vector was used so that total transfected DNA is 110 ng/well). Stimulation with 1 μM Dex or 
with vehicle was performed for 24 h. The immunoblots below the graph indicate the transfection efficiency. 
The graph represents pool data from three independent experiments (B) Transfection of HEKT293T cells 
in 10 cm plates with 3 μg Flag-GR (86 kDa) or Flag-GR S211 A (86 kDa) along with 4 μg of YFP-STRN3 
(122 kDa) was performed and stimulation with 1 μM Dex or vehicle. The cells were lysed and processed 
for co-immunoprecipitation using M2-Flag beads and for immunoblot using anti-Flag and anti-STRN3 
antibodies. The experiment was repeated three times with similar results (full-length blots are provided in 
Supplementary S12).
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Figure 7. PPP2CA mediates the effect of STRN3 on GR phosphorylation. (A) Identification of common 
interacting phosphatases for STRN3 and GR using Ingenuity Pathway Analysis (IPA) database. (B) A549 
cells were transfected in 10 cm plates with 50 nM of control (lanes 1–4) or with PPP2CA (lanes 5–8) siRNA. 
After 24 h, Flag-STRN3 (lanes 3–4, 7–8) or mock (lanes 1–2, 5–6) plasmids were over-expressed (6 μ of total 
DNA was transfected per plate). After 48 h, the cells were treated with vehicle or 1 μM Dex for 2 h and lysed. 
The nuclear fractions of the lysates were analyzed by immunoblotting against GR phosphorylated at S211, 
total GR (86 kDa), (Flag-) STRN3 (96 kDa), PPP2CA (35 kDa) and PARP (116 kDa, nuclear marker). Total 
GR expression was identified in a separate immunoblot to avoid multiple stripping of the membrane. This 
is a representative experiment out of three independent experiments that have been performed with similar 
results. (C) Co-immunoprecipitation experiment in HEK293T cells for the complexes GR/STRN3/PPP2CA, 
GR/PPP2CA and STRN3/PPP2CA (in 10 cm plates). Over-expression of 4 μg PPP2CA (lane 1) and over-
expression of 4 μg CFP-GR (lane 2) serve as negative controls. Additionally, the cells were transfected with 
3 μg Flag-STRN3, 4 μg CFP-GR and 4 μg PPP2CA (lanes 3–4) or with 3 μg Flag-GR and 4 μg PPP2CA (lanes 
5–6) or with 3 μg Flag-STRN3 and 4 μg PPP2CA (lanes 7–8). 48 h after transfection, the cells were treated with 
vehicle or with 1 μM Dex as indicated (2 h). The lysates were used for IP assays using M2-Flag beads and the 
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MR-dependent ERK phosphorylation without affecting EGF-induced ERK phosphorylation or genomic MR sig-
naling43. The relevance of striatin for MR signaling is further suggested by the analysis of heterozygous striatin 
KO mice with low striatin levels and salt sensitive blood pressure. In this model, the pAKT/AKT ratio, as part of 
another potential non-genomic MR signaling pathway, is reduced while MR expression and genomic signaling 
are increased44. Collectively, our data reporting the effect of STRN3 on GR and the first evidences for a possible 
effect on the nuclear actions of PR and PPARα, together with the published findings by other research groups 
on other steroid receptor members, pinpoint the STRN family of proteins as a prominent regulator of nuclear 
receptor actions.
Co-immunoprecipitation analysis revealed the possibility of the formation of a trimeric complex among 
GR, STRN3 and PPP2CA, however, with the present data we cannot conclude whether these interactions are 
direct, and/or whether more proteins are involved. In the absence of STRN3 over-expression, GR was not able 
to interact with PPP2CA in HEK293T. However, the interaction of PPP2CA with GR has been described pre-
viously to contribute to corticosteroid sensitivity in severe asthma by dephosphorylation of GR S226, a mod-
ification regulating receptor nuclear export30, 45. In our study, over-expression of STRN3 and the subsequent 
recruitment of PPP2CA did not affect receptor shuttling. The discrepancy between results may be attributed 
to the different cell lines tested. We believe that PPP2CA needs an intermediate protein to form the complex in 
which GR is recruited. Here, STRN3 serves as the scaffold protein that will attract PPP2CA to a complex with 
GR. Nevertheless, in a different cell line and under different conditions, PPP2CA might use another scaffold 
protein to engage GR in the complex. Another example in which STRN3 is an essential part of a trimeric com-
plex is with the antioxidant protein DJ-1 and the survival kinase Akt, suggestive of a role in neuroprotection46. 
Combining the co-immunoprecipitation data for (phosphorylated) GR with the immunofluorescence-based 
endogenous co-detection between GR and STRN3, we bring forward that the formation of a protein complex 
between ligand-activated GR, STRN3 and PPP2CA most likely occurs in the nucleus, hereby influencing the 
transactivation capacity of GR.
Co-immunoprecipitation experiments with GR deletion mutants indicated that predominantly the LBD and, 
to a lesser extent, the very C-terminal part of the NTD spanning into the DBD of the GR are needed to interact 
with STRN3 while the LBD is crucial for the binding of endogenous PPP2CA. STRN3 oligomerizes and inter-
acts with PPP2CA via its coiled-coil domain31. Collectively, we deduct that GR and STRN3 might interact in an 
antiparallel orientation so that the C-terminal domain of GR is in close proximity with the coiled-coil domain of 
STRN3, which are also the respective domains for PPP2CA binding.
Apart from the well-studied role of the GR-mediated transrepression pathway in immunosuppression47, 48, 
the transactivation pathway of GR has re-gained attention due to the activation of a cluster of genes with potent 
anti-inflammatory actions such as GILZ and DUSP149. One of the causes leading to GCR, a state in which the 
patients do not respond to the GC treatment50, is the elevated levels of Tumor Necrosis Factor (TNF); a potent 
pro-inflammatory cytokine33. TNF and GR interfere with each other’s signaling pathway, resulting in a mutual 
inhibition51. As proven before in vitro and in vivo treatment with Dex followed by TNF, diminished the efficiency 
of Dex and the subsequent GR activity by almost 50%, (Supplementary S9)52, 53. Preliminary data indicate that in 
liver samples from wild type mice injected with TNF, endogenous mRNA levels of STRN3 were induced upon 
TNF treatment (Supplementary S10A). It would be interesting to further investigate whether in acute inflam-
matory conditions induced by TNF, the inflammatory environment may alter the interactome of GR, favoring 
the up-regulation of co-factors with a potential negative effect on GR functionality, as a possible mechanism 
leading to GCR (Supplementary S10B). In conclusion, STRN3, the novel inhibitor interaction partner of GR, may 
contribute to a continuous recruitment of PPP2CA at the GR-STRN3 complex followed by a dephosphorylation 
of GR at S211, resulting in a decrease of GR transactivation (Fig. 8C). The mechanism may involve a platform 
created by GR and STRN3, which further assists PPP2CA to anchor to the complex and to mediate the dephos-
phorylation of GR at S211, linking to an overall diminished transactivation function of GR.
Methods
Plasmids. The MAPPIT pCLG-hGRα bait vector was generated by cloning the full size human GRα coding 
sequence in the pCLG vector backbone, which was described previously54. The pMG1-hSTRN3 prey vector was 
obtained by Gateway recombinatorial transfer of a full size STRN3 ORF cDNA from an entry clone selected from 
the human ORFeome collection version 5.155 into the pMG1 destination vector, as reported before56. A STAT3-
responsive firefly reporter plasmid, pXP2d2-rPAP1-Luc57, was used to generate the MAPPIT readout.
precipitates were analyzed with immunoblotting against (Flag-) STRN3 (96 kDa), (CFP- or Flag-) GR (117 or 
86 kDa, respectively) and PPP2CA (35 kDa) (11 μg of total DNA was transfected per plate) (full-length blots 
of (B,C) are provided in Supplementary S16 and S17, respectively). (D) The complexes Flag-GR/YFP-STRN3/
PPP2CA and Flag-GR/PPP2CA were examined for their phosphatase activity. HEK293T cells (in 10 cm plates) 
were transfected with 4 μg PPP2CA (negative control) or with 3 μg Flag-GR, 4 μg YFP-STRN3 and 4 μg PPP2CA 
or with 3 μg Flag-GR and 4 μg PPP2CA. All the samples were treated with 1 μM Dex for 2 h. The complexes were 
precipitated with M2-Flag beads and then incubated with Flag peptide in order to detach the complexes from 
the beads. Then the samples were processed for the phosphatase assay (the assay is described in the section of 
Methods). Additional negative controls: no-substrate condition (diluent) and total lysate from cells stimulated 
with 100 nM Okadaic acid, a phosphatase inhibitor. Positive control: total cell lysate (11 μg of total DNA was 
transfected per plate). B, C and D are representations of a series of triplicate experiments that all yielded similar 
results.
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The functional reporter assays involved the following plasmids: GRE-Luc reporter plasmid, which 
contains two copies of the glucocorticoid response element (GRE) and the pHD-Luc that contains the 
PPARα response element58. The human STRN3a from the human ORFeome V5.1 collection was cloned 
in two different vectors, pMet7-Flag-STRN3 and pMet7-YFP-STRN3a. hGRα and hPPARα were cloned 
into a pMet7-Flag vector, a pECFP-GRα and a pMet7-Flag-PPARα, respectively. The GR mutant with 
serine 211 (S211) mutated into Alanine (GR S211A) was generated via site directed mutagenesis of 
pEF-Flag-human GRα and checked by sequencing analysis. The primers used in PCR containing the muta-
tion are the following: CCCCAGGTAAAGAGACGAATGAGGCTCCATGGAGATCAGACCTGTTG and 
Figure 8. The formation of the trimeric complex GR/STRN3/PPP2CA is dependent on the ligand-binding 
domain of GR. (A) Representation of the GR deletion mutants that were used for mapping GR domains 
important for the formation of the trimeric complex. (B) HEK293T cells were transfected in 10 cm plates with 
3 μg of the different Flag-GR deletion mutants along with 4 μg of YFP-STRN3 (122 kDa). 48 h post-transfection 
the cells were lysed and processed for co-immunoprecipitation with M2-Flag beads (7 μg of total DNA was 
transfected per plate). The resulting complexes were analyzed with gel electrophoresis and immunoblotting 
using antibodies against Flag, STRN3 and PPP2CA. In this experiment PPP2CA was not over-expressed and 
we rely on the endogenous PPP2CA binding to the complex. This is a representation of a series of triplicate 
experiments that all yielded similar results (full-length blots are provided in Supplementary S18). (C) Proposed 
model for the formation of the trimeric GR-STRN3-PPP2CA complex. GR LBD (and to a lesser extent GR 
DBD) binds STRN3, allowing PPP2CA to be recruited and to dephosphorylate GR, leading to hampered 
transactivation. GR with its protein domains (NTD, DBD, LBD) is depicted in grey. P stands for phosphorylated 
S211. The purple circle represents the ligand, Dex.
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CAACAGGTCTGATCTCCATGGAGCCTCATTCGTCTCTTTACCTGGGG. GR deletion mutants were cloned 
in pMet7-Flag and were chemically synthesized by Gene9 containing att sites for gateway cloning in the destina-
tion vectors. The mutants span the following deletions: Del1-401, Del1-416, Del417-486, Del417-777 and Del487-
777. The human PPP2CA plasmid is from addgene and is cloned into a pBABE zeo vector59. pMet7-Flag-empty 
vector was used as mock DNA where appropriate, to reach the same amount of transfected DNA per well for all 
set-ups.
Antibodies. Anti-GR (rabbit, H300, Santa cruz Biotechnology), anti-PPP2CA (rabbit, Proteintech), 
anti-Phosphorylated S211 Glucocorticoid receptor (rabbit, cell signaling technology), anti-STRN3 [1) N-20, 
goat polyclonal, sc:16853, Santa cruz Biotechnology, used in immunofluorescence experiments, 2) S68, mouse 
monoclonal, MAI-46461, Thermo Scientific, 3) mouse monoclonal, 05-1115, Millipore] (1 and 2 successfully 
detect over-expressed STRN3 in western blots), anti-Flag (mouse, Sigma), anti-Flag (rabbit, Sigma), anti-Lamin 
A/C (mouse, Cell signaling technology), anti-GAPDH (rabbit, Abcam), anti-PARP-1 (H-250, Santa cruz 
Biotechnology), horseradish peroxidase-conjugated anti-mouse and anti-rabbit from Jackson Immunoresearch 
laboratories, Pierce donkey anti-rabbit secondary antibody dylight 800 or 680 and Pierce donkey anti-mouse 
secondary antibody dylight 680 (Thermo Scientific).
Cell culture. Human embryonic kidney T cells (HEK293T) and human lung carcinoma (A549) cells, basal or 
stably transfected with recombinant NF-κB- or GRE-dependent reporter genes60 were maintained in DMEM plus 
fetal bovine serum in a humidified atmosphere of 5% CO2 at 37 °C.
MAPPIT. HEK293T cells were cultured in 96-well microtiter plates in DMEM supplemented with 10% fetal 
bovine serum and transfected with bait (25 ng per well), prey (50 ng per well) and reporter (5 ng per well) plas-
mids, via standard calcium phosphate transfection, as described earlier56. Twenty-four hours after transfection, 
triplicate wells were treated either with vehicle (medium, non-active MAPPIT system) or leptin (100 ng/ml) plus 
medium or leptin plus Dex (1 µM). Another 24 h later, luciferase activity was measured using the Luciferase Assay 
System kit (Promega) on an Envision plate reader (Perkin Elmer)21. Luciferase fold change was determined by 
calculating the ratio of either leptin + medium/vehicle or leptin + Dex/vehicle (Fig. 1C). The amount of DNA 
transfected per well was kept constant to 100 ng/well by addition of empty vector plasmid.
Indirect Immunofluoresecence analysis. Cell fixation, methanol permeabilization and staining of 
A549 or HeLa cells were performed according to Cell Signaling guidelines. GR was visualized with the GR 
polyclonal (H300) antibody (Santa Cruz) while STRN3 was visualized with the STRN3 monoclonal (N20) 
antibody (Santa Cruz), both used at 1:200, followed by probing with Alexa Fluor® 488 (Invitrogen) and/
or Alexa Fluor® 568 (Invitrogen), respectively at a concentration of 1:1000. Nuclei were visualized using 
4′,6-diamidino-2-phenylindole (DAPI) staining at a concentration of 1:100. A motorized inverted IX81 FluoView 
FV1000 laser scanning confocal microscope (Olympus) was used to record high-resolution images.
Reporter gene assay. HEK293T cells were transfected with calcium phosphate. Plasmids encoding GR, 
PR and PPARα along with their respective response element-dependent reporters, GRE-Luc, PRE-Luc and 
PPRE-Luc were over-expressed in presence of a constitutive β-galactosidase expressing plasmid and in absence 
or presence of increasing amounts of Flag-STRN3 plasmid, as indicated in Figures’ legends. The experiments were 
performed in 96 well plates. 24 h after transfection, the medium was replaced with Optimem and 48 h after trans-
fection the cells were stimulated with the respective nuclear receptor ligands for 6 h. Firefly luciferase read-outs 
were normalized to β-galactosidase activity.
Small interfering RNA (siRNA) transfection. All siRNAs used in this study were purchased from 
Dharmacon. Two different siRNA specific for human STRN3 were used to confirm the specificity of the assay 
[siGenome Smartpool (M-019145-01-0005) and On-target plus Smartpool (L-019145-01-0005)]. For human 
PPP2CA silencing, we used the On-target plus Smartpool siRNA (L-003598-01-0005). As a control siRNA, 
siControl Nontargeting was used. A549 cells were transfected with a final concentration of 50 nM with the 
above-mentioned siRNAs with Dharmafect 1 (Thermo Scientific) reagent according to the manufacturer’s 
instructions. Using reporter gene assays, 72 h after siRNA transfection, the cells were treated as specified under 
“Results”. In case of an additional plasmid transfection step, 24 h after siRNA transfection, the medium was 
changed to Optimem followed by plasmid DNA transfection of A549 cells using the Lipofectamine Plus protocol 
according to the manufacturer’s instructions. 48 h later, the cells were further processed for analysis.
Quantitative RT-PCR (qPCR). Total RNA was prepared from A549 cells or mouse liver samples using the 
RNeasy mini kit (Qiagen). cDNA was synthesized using iScriptTM Advanced cDNA Synthesis Kit from Bio-Rad 
and analyzed using the Power SYBR Green Master Mix (Applied Biosystems). Expression levels were calculated 
using the comparative Ct method, normalized to the best performing housekeeping genes, GAPDH and β-actin, 
determined by Genorm61.
Co-immunoprecipitation and Western analysis. Experiments were performed in 10 cm petri dishes. 
HEK293T cells were harvested and homogenized in lysis buffer A (10 mM Hepes pH 7.5, 1.5 mM MgCl2, 10 mM 
KCL, 0.5 mM DTT, 0.1% NP-40 supplemented with a protease inhibitor cocktail (Roche)). Samples were sub-
jected to two freeze-thaw cycli (−70 °C). Lysates were cleared by centrifugation at 13.000 rpm at 4 °C and incu-
bated with 20 μl of Anti-Flag M2 Affinity Gel (Sigma Aldrich) overnight at 4 °C. Beads are washed 4× in buffer A 
supplemented with 150 mM NaCl and 0.5% Triton-X 100, re-suspended in Laemmli buffer and boiled for 1 min 
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at 95 °C. Immunoprecipitates were either frozen at −20 °C or used for Western analysis using antibodies (diluted 
in blocking buffer at 1/1000 overnight) against GR, STRN3, Flag and PPP2CA.
Nuclear and cytoplasmic fractionation. Cells were collected and resuspended in 200 μl of ice-cold Buffer 
1 pH 7.5 (10 mM Hepes, 10 mM KCL, 1 mM MgCl2, 5% glycerol, 0.5% EDTA, 0.5% EGTA) supplemented with 
protease inhibitor (Roche) and incubated on ice for 15 min. 1 μl 10% NP-40 was added prior to a vortexing step 
for 10 sec. The cytoplasmic fraction was collected after centrifugation for 5 min at 14.000 rpm at 4 °C. To the 
remaining pellet, 100 μl of Buffer 2 pH 7.5 (10 mM Hepes, 1% NP-40, 1 mM MgCl2, 400 mM NaCl, 10 mM KCl, 
20% glycerol, 0.5 mM EDTA, 0.5 mM EGTA) was added, followed by a vortexing step for 2 sec and incubation 
at 4 °C for 30 min on a shaker. The nuclear fraction was collected after centrifugation for 15 min at 14.000 rpm at 
4 °C.
Phosphatase activity assay. The DuoSet® IC kit, specific for the quantification of human/mouse/rat PP2A 
activity (R&D systems), was used according to the manufacturer’s instructions. This DuoSet® IC activity assay 
contains the basic components required for the development of capture assays to measure the activity of PPA in 
lysates. An immobilized capture antibody specific for the catalytic subunit of PP2A binds both active and inactive 
PP2A. After washing away unbound material, a synthetic phosphopeptide substrate is added that is dephospho-
rylated by active PP2A to generate free phosphate and phosphorylated peptide. The free phosphate is detected 
by a sensitive dye-binding assay using malachite green and molybdic acid. By calculating the rate of phosphate 
release, the activity of PP2A is determined. As a positive control, we used total lysate, and as negative controls 
we used lysate stimulated with the PP2A/B specific phosphatase inhibitor, Okadaic acid (100 nM) (Cell signaling 
technology, #5934). As a control for immunoprecipitation, we used over-expression of PPP2CA in absence of 
Flag-GR.
Reagents. Recombinant mouse and human TNF was produced in E. coli and purified to homogeneity in our 
laboratories. Mouse TNF and human TNF had a specific activity of 1.2 × 108 IU/mg or 3.7 × 107 IU/ml, respec-
tively, and no detectable endotoxin contamination. Dexamethasone, Progesterone and GW7647 were purchased 
from Sigma.
Statistical analysis. Data are expressed as the mean ± S.E. Student’s t-tests (for comparisons between two 
groups) or one-way ANOVA analysis (for comparisons of ≥ 3 groups) followed by Tukey’s post hoc test was used 
for the statistical analyses, with 95% confidence intervals and with unpaired two-tailed analysis of variance. Error 
bars in the figures represent the mean ± S.E. *, **, *** represent p < 0.05, p < 0.01 and p < 0.001, respectively.
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